Cellogen Therapeutics
“Cellogen Therapeutics” is biotech startup which is
striving today to come up with innovative cell
therapy-based solutions for a healthy tomorrow.
Our Research
We at Cellogen Therapeutics are using advanced technologies to provide affordable therapies for hard-to-treat and congenital human diseases. Our universal as well as personalised therapeutic products are developed using the advanced technology platforms. We are developing the next-generation CAR-T and NK cell-based therapies using Genome editing approaches and therapeutic viral vectors.
Innovation
- Novel CAR (Chimeric Antigen Receptor) constructs for B cell malignancies (Indigenously conceptualized & synthesized)
- Innovative gene editing solution for beta hemoglobin disorders
- Innovative vector delivery methods
- Customized products
- State-of-the-art manufacturing platforms
- Why Cellogen Therapeutics has the potential to lead the revolution?
Pipeline
- NOVEL CAR Constructs for B-Cell Malignancies (AUTOLOGOUS)
- NOVEL CAR construct for Multiple Myeloma (AUTOLOGOUS)
- NOVEL CAR Constructs for B-Cell Malignancies (ALLOGENIC OFF-THE-SHELF)
- NOVEL CAR-T cells for Solid Tumors (AUTOLOGOUS AND ALLOGENIC)
- Virus specific CAR-T cells
- Targeted mutant panel cancer cell lines
- Ex vivo genome-edited cell therapy product for sickle cell disease and transfusion dependent thalassemia.
